Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pyruvate Clear all
Terminated Phase 1 Interventional

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00332215
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Sodium Pyruvate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

HP Pyruvate MRI in Cancers

NCT05697406
View directory record Official record
Conditions
Image, Warburg Effect, Tumors
Interventions
Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 24, 2026, 8:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225
View directory record Official record
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
Etavopivat
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Ocala, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Completed No phase listed Observational

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

NCT02340689
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Genetic Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Day and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 24, 2026, 8:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

NCT04824365
View directory record Official record
Conditions
COVID-19
Interventions
Sodium Pyruvate, Saline
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Virginia Gardens, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 24, 2026, 8:46 PM EDT
Withdrawn Phase 2 Interventional

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

NCT03581500
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Level Greater Than Ten, Stage IIB Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 24, 2026, 8:46 PM EDT
Suspended Phase 1 Interventional

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

NCT05866679
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Hyperpolarized 13-C-pyruvate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Months and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

NCT00262652
View directory record Official record
Conditions
Moderate Asthma
Interventions
sodium pyruvate
Drug
Lead sponsor
Emphycorp
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

NCT07510607
View directory record Official record
Conditions
Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions
HP 13C pyruvate injection, MRI Scanner
Drug · Device
Lead sponsor
Ari Green
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

NCT03853798
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT02526368
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Terminated Early Phase 1 Interventional

MRI With C13 Pilot Study Prostate Cancer

NCT02450201
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 24, 2026, 8:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

NCT04871815
View directory record Official record
Conditions
Long COVID
Interventions
sodium pyruvate nasal spray
Drug
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Phase 2 Interventional

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208
View directory record Official record
Conditions
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

NCT03685721
View directory record Official record
Conditions
Sickle Cell, PKLR Variants, Adenosine Triphosphate Activities
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Suspended Phase 1 Interventional

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

NCT05873699
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Hyperpolarized 13-C-pyruvate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
View directory record Official record
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Phase 1 Interventional

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03559699
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Interventions
AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Oakland, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 24, 2026, 8:46 PM EDT
Recruiting Phase 1 Interventional

Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

NCT03830151
View directory record Official record
Conditions
Primary Brain Neoplasm
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Terminated Phase 2 Interventional Results available

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

NCT03450707
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Thiamine 500 mg IV, Placebo
Drug · Other
Lead sponsor
Michael Donnino
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 24, 2026, 8:46 PM EDT
Suspended Phase 2 Interventional

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

NCT03952598
View directory record Official record
Conditions
Glioma, Gliomas, High Grade Glioma, Malignant Glioma, Low Grade Glioma
Interventions
HP 13C Pyruvate, 3T MRI scanner
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 8:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway

NCT03480594
View directory record Official record
Conditions
Fatty Liver
Interventions
MRI Tracer
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 24, 2026, 8:46 PM EDT